Current Valuation
N/A
As of October 23, 2024
Total Funding Raised
$261.1M
Last Round
Later Stage VC

$175.0M

Last Funding
Oct 2024

Funding date

Capital Efficiency
N/A

Valuation / Funding

Funding History & Valuation Timeline
Complete history of all funding rounds and valuation milestones

No funding history available

Funding data has not been imported for this company yet

Valuation Analysis

Current Valuation Metrics

Alpha-9 Oncology is currently valued at N/A as of October 23, 2024. The company has raised a total of $261.1M in funding.

Investment Perspective

Alpha-9 Oncology's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.

Track Alpha-9 Oncology Valuation Updates

Get notified when Alpha-9 Oncology raises new funding or valuation changes

What is Alpha-9 Oncology Worth in 2025?

As of 2025, Alpha-9 Oncology is valued at N/A, based on the company's Later Stage VC funding round in October 23, 2024. This valuation positions Alpha-9 Oncology as one of the leading private companies in the sector.

Alpha-9 Oncology Valuation History

Alpha-9 Oncology's funding history demonstrates steady growth and investor confidence.

How Alpha-9 Oncology Valuation is Determined

Private company valuations like Alpha-9 Oncology's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:

  • Revenue growth and financial performance
  • Market opportunity and total addressable market (TAM)
  • Competitive positioning and market share
  • Management team strength and execution capability
  • Technology and intellectual property
  • Industry trends and investor sentiment

Alpha-9 Oncology Valuation FAQs

Is Alpha-9 Oncology profitable?

Alpha-9 Oncology has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.

How does Alpha-9 Oncology's valuation compare to competitors?

Alpha-9 Oncology is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.

When will Alpha-9 Oncology IPO?

Alpha-9 Oncology has not announced plans for an initial public offering. Until an IPO, investors can access Alpha-9 Oncology shares through secondary market platforms.